BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications
about
Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistanceMicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis.Measures for the degree of overlap of gene signatures and applications to TCGA.IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal CarcinomasRegulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains.Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer.Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK1 and 2.Important molecular genetic markers of colorectal cancer.Modulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs.Current and future molecular diagnostics in non-small-cell lung cancer.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Telomere length regulation through epidermal growth factor receptor signaling in cancer.Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.Stabilization of Sur8 via PKCα/δ degradation promotes transformation and migration of colorectal cancer cells.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma.Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials.A dual role for glucocorticoid-induced leucine zipper in glucocorticoid function: tumor growth promotion or suppression?Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver CancerLow serum gastrin associated with ER breast cancer development via inactivation of CCKBR/ERK/P65 signaling
P2860
Q26795609-29FF497B-A8E4-4662-93FD-0FA845FB33C9Q33618363-0B7DF832-E99A-4C71-8C6C-0E190C21DD11Q36060588-D9A0B966-E451-41DC-B30B-772929A566EEQ36103378-67FB14E8-A60B-4981-927E-95A2370B882AQ36472281-89E35309-CB55-475C-AB55-CB6E354A831FQ36823916-0B6E185A-AD5E-44AE-A441-98023F79CC46Q37096248-C74B0D5A-6480-4F0D-88EA-BFD3F384A22FQ37402581-C4B6FD6C-C776-43DF-AC95-0C3B7BF4F6E6Q37619838-543C7DEA-4A61-4E09-85AC-436D574A9976Q37619856-6C7A3788-F6DF-4EBE-9AFA-E82AF5BC6B57Q37729599-20CD6819-9AF7-4937-8FEB-862F86EAAF54Q38543780-C37F69E3-D8F9-442C-AFC2-47831765CCB1Q38794338-5977044D-0258-4BA6-94BA-B3DED9CF32CBQ39233197-E6F41773-A384-45BD-B085-695AFB210B57Q39455829-DE68AAF6-DB97-43F8-AC46-4EB8F1AAEA36Q44239255-A2B85264-A07D-4A1C-BC70-8081129158B7Q47614611-72816098-4904-4C5A-80EE-FF069BDFAED3Q47682948-5E105CAA-3316-42D0-83F9-F3583E29D7D8Q49312207-D9BE767D-38C1-4009-A1C3-A653C5F99698Q49887919-FC190424-5311-4498-BC3B-142870AA3A9AQ52607333-3CEE609F-C01B-48F0-B5A2-A70F885F3005Q52801320-6797E1F8-5FE4-473E-85F0-9D70D164C5F3Q55103799-AB7F24AA-7502-4B3A-9E48-FEBA53A9D3EAQ55384201-BC6B20FD-F82C-45F6-B87E-529BCDB5B4D5Q56969146-C270E7A5-39AD-42E0-9A65-B55A0580039EQ58774122-E1A3DE83-57A5-4E04-8A51-760BF55038FC
P2860
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@ast
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@en
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@nl
type
label
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@ast
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@en
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@nl
prefLabel
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@ast
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@en
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
BRAF vs RAS oncogenes: are mut ...... g and therapeutic implications
@en
P2093
Alexander Pintzas
Eftychia Oikonomou
Evangelos Koustas
Maria Goulielmaki
P2860
P304
P3181
P356
10.18632/ONCOTARGET.2555
P407
P5008
P577
2014-12-15T00:00:00Z